• Brefeldin A Workflows for ER–Golgi Stress Studies

  2026-09-20

  Brefeldin A converts ER–Golgi trafficking disruption into a measurable workflow for secretion, organelle morphology, ER stress, and cancer-cell assays. This guide combines practical BFA dosing with controls that help distinguish trafficking-specific effects from nonspecific cytotoxicity.

• Octenidine dihydrochloride: Assay Workflows

  2026-09-19

  Build more reproducible membrane-disruption, susceptibility, and biofilm assays with Octenidine dihydrochloride. This guide combines practical formulation advice with reference-backed comparisons, controls, and troubleshooting for antimicrobial research.

• Brefeldin A Workflows for ER Stress Research

  2026-09-18

  Use Brefeldin A as a controlled trafficking perturbation to connect ER-to-Golgi transport failure with ER stress, secretion defects, and cell death. This practical guide combines dose and timing design with UBR1/UBR2-focused assays and cancer-cell troubleshooting.

• 10074-G5: A c-Myc Inhibitor Workflow

  2026-09-18

  Build a mechanism-first cancer research workflow around 10074-G5, linking c-Myc/Max disruption to apoptosis, cell cycle arrest, and EMT reversal. The approach is especially useful for testing the miR-196a–c-Myc–TERT–NFκB axis in esophageal adenocarcinoma while preserving orthogonal controls and practical troubleshooting.

• Brefeldin A: ER Stress Workflow & Cell Assays

  2026-09-17

  Brefeldin A converts ER-to-Golgi trafficking disruption into a practical platform for studying secretion, ER stress, and cancer-cell fate. This guide links dose–time design with trafficking, apoptosis, migration, and protein-quality-control readouts while highlighting controls that prevent cytotoxicity from being mistaken for mechanism.

• Total RNA Extraction Reagent in Ferroptosis Studies

  2026-09-17

  Total RNA Extraction Reagent (Trizol) supports reproducible transcript analysis in radiation-oncology research. This article explains how RNA isolation choices shape interpretation of DHODH, ferroptosis, and macrophage-polarization findings after carbon-ion radiotherapy.

• SW033291: A 15-PGDH Assay Strategy

  2026-09-16

  SW033291 is a potent 15-PGDH inhibitor for dissecting prostaglandin E2 elevation across biochemical, cellular, hematopoietic, and regenerative models. This article presents an assay-centered framework that separates target engagement from tissue-level outcomes and clarifies how recent muscle-repair findings should guide experimental design.

• Biotin-HPDP: Reversible Thiol Labeling Guide

  2026-09-16

  Biotin-HPDP is a sulfhydryl-reactive biotinylation reagent for selective, reversible labeling of accessible thiols. Its pyridyl disulfide chemistry supports thiol-specific protein labeling, streptavidin-based detection, affinity purification, and controlled release with reducing agents.

• Brefeldin A Workflows for ER Stress Research

  2026-09-15

  Brefeldin A converts a trafficking perturbation into a practical way to study ER stress, secretion defects, and cell-fate decisions in parallel. This workflow shows how BFA can distinguish transport-dependent phenotypes from downstream apoptosis while improving assay reproducibility in cancer and cell-biology models.

• Filipin III for Membrane Cholesterol Detection

  2026-09-15

  Filipin III is a polyene macrolide antibiotic used for cholesterol detection in membranes and membrane cholesterol visualization. Its cholesterol-dependent aggregation, fluorescence decrease, and sterol-selective vesicle lysis make it useful for localization studies, but not a standalone quantitative assay for oxysterol signaling.

• Brefeldin A Workflows for ER Stress and Trafficking

  2026-09-14

  Brefeldin A (BFA) gives researchers a controllable way to perturb ER-to-Golgi trafficking, secretion, ER stress, and cancer-cell survival in the same experimental framework. This guide translates the compound’s mechanism into practical workflows, including endothelial-assay safeguards inspired by a sepsis biomarker study.

• LY2109761: Dual TGF-β Receptor Kinase Inhibitor

  2026-09-14

  LY2109761 is a TGF-β receptor type I and II dual inhibitor that competitively targets the ATP-binding site of TβRI kinase. Product information reports nanomolar kinase potency and preclinical activity in pancreatic cancer, glioblastoma, bone-tumor, and fibrosis models, while the cited GBM study supports the biological importance of Smad-dependent signaling rather than direct clinical efficacy.

• SW033291: A Practical 15-PGDH Workflow

  2026-09-13

  SW033291 turns 15-PGDH inhibition into a measurable workflow spanning PGE2 assays, hematopoietic models, and muscle regeneration research. This guide connects biochemical potency with experimental design, combination studies, and troubleshooting for semaglutide-associated muscle recovery models.

• Triple-Pathway Inhibition in BRAFV600E Melanoma

  2026-09-12

  The reference study shows that RocA-induced stress in BRAFV600E melanoma activates temporally distinct ERK1/2–EZH2 and AKT1–eIF4E resistance programs. Its central practical finding is that concurrent inhibition of eIF4F, EZH2, and AKT1 can improve responses in RocA- and vemurafenib-resistant models, although the evidence remains preclinical and melanoma-specific.

• Nav1.6–NHE1 Signaling in Glioblastoma

  2026-09-11

  A 2025 Molecular Biology Reports study identifies a functional Nav1.6–NHE1 axis that supports glioblastoma proliferation and migration while sustaining ERK-AKT survival signaling. Its combined genetic and pharmacological design links ion regulation with measurable changes in DNA synthesis, motility, and apoptosis, although validation beyond cultured cell models is still needed.

8565 records 1/571 page Next 12345 下5页 Last page